Emergent BioSolutions (EBS) Intangibles (2013 - 2026)
Emergent BioSolutions (EBS) posted quarterly Intangibles of $470.4 million for Q1 2026, down 3.05% year-over-year from $485.2 million in Q1 2025, and up 7.77% quarter-over-quarter from $436.5 million in Q4 2025.
Emergent BioSolutions (EBS) Intangibles (2013 - 2026) Analysis & Trends
Emergent BioSolutions' Intangibles history runs 14 years deep, the most recent figure standing at $470.4 million for Q1 2026.
- In Q1 2026, Intangibles fell 3.05% year-over-year to $470.4 million; the TTM figure through Mar 2026 stood at $470.4 million (down 3.05% YoY), while the FY2025 annual figure was $436.5 million, down 12.96% from the prior year.
- Intangibles for Q1 2026 stood at $470.4 million, up from $436.5 million in the prior quarter.
- The five-year high for Intangibles was $728.8 million in Q4 2022, with the low at $436.5 million in Q4 2025.
- The 5-year median for Intangibles is $550.4 million (2024), against an average of $552.3 million.
- The sharpest annual moves came in 2022 and 2023: Intangibles gained 20.54% in 2022, then dropped 22.26% in 2023.
- Emergent BioSolutions' Intangibles stood at $728.8 million in 2022, then fell by 22.26% to $566.6 million in 2023, then dropped by 11.49% to $501.5 million in 2024, then declined by 12.96% to $436.5 million in 2025, then grew by 7.77% to $470.4 million in 2026.
- Business Quant data shows EBS's Intangibles at $470.4 million in Q1 2026, $436.5 million in Q4 2025, and $452.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 3.45 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 918.00 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 21.28 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 13.68 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 2.23 Bn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 3.20 Bn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 1.12 Bn |
| 10 | Emergent BioSolutions | 251.81 Mn | 110.91 Mn | 137.20 Mn | 261.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 261.80 Mn |
| Mar 31, 2026 | 470.40 Mn |
| Dec 31, 2025 | 436.50 Mn |
| Sep 30, 2025 | 452.70 Mn |
| Jun 30, 2025 | 469.00 Mn |
| Mar 31, 2025 | 485.20 Mn |
| Dec 31, 2024 | 501.50 Mn |
| Sep 30, 2024 | 517.80 Mn |
| Jun 30, 2024 | 534.10 Mn |
| Mar 31, 2024 | 550.40 Mn |
| Dec 31, 2023 | 566.60 Mn |
| Sep 30, 2023 | 582.80 Mn |
| Jun 30, 2023 | 592.80 Mn |
| Mar 31, 2023 | 608.90 Mn |
| Dec 31, 2022 | 728.80 Mn |
| Sep 30, 2022 | 724.90 Mn |
| Jun 30, 2022 | 576.60 Mn |
| Mar 31, 2022 | 590.60 Mn |
| Dec 31, 2021 | 604.60 Mn |
| Sep 30, 2021 | 618.60 Mn |